Ocular cicatricial pemphigoid

Authors

  • Virginia Ruth López Gamboa Cordoba Hospital, Cordoba, Cordoba, Argentina
  • María Belén Castaño Cordoba Hospital, Cordoba, Cordoba, Argentina
  • Ingrid Videla Cordoba Hospital, Cordoba, Cordoba, Argentina
  • Valeria Elizabeth Rossello Cordoba Hospital, Cordoba, Cordoba, Argentina
  • Leandro Rodolfo Van Caester Cordoba Hospital, Cordoba, Cordoba, Argentina
  • Gabriela Sambuelli Cordoba Hospital, Cordoba, Cordoba, Argentina
  • Mariana Beatríz del Valle Papa Cordoba Hospital, Cordoba, Cordoba, Argentina
  • Susana Pereyra Cordoba Hospital, Cordoba, Cordoba, Argentina

Keywords:

mucous membrane pemphigoid, ocular cicatricial pemphigoid, treatment

Abstract

Mucous membrane pemphigoid is a chronic inflammatory autoimmune bullous disease, which includes a purely ocular type known as ocular cicatricial pemphigoid. Throughout its clinical course, ocular cicatricial pemphigoid causes erosions and conjunctival damage; lesions which if not treated on time may evolve into blindness. We present three cases of ocular cicatricial pemphigoid, which were treated with systemic immunosupression and topical therapy.

Author Biographies

Virginia Ruth López Gamboa, Cordoba Hospital, Cordoba, Cordoba, Argentina

Specialist in Internal Medicine and Dermatology

María Belén Castaño, Cordoba Hospital, Cordoba, Cordoba, Argentina

Dermatology Specialist

Ingrid Videla, Cordoba Hospital, Cordoba, Cordoba, Argentina

Dermatology Resident

Valeria Elizabeth Rossello, Cordoba Hospital, Cordoba, Cordoba, Argentina

Dermatology Resident

Leandro Rodolfo Van Caester, Cordoba Hospital, Cordoba, Cordoba, Argentina

Dermatology Resident

Gabriela Sambuelli, Cordoba Hospital, Cordoba, Cordoba, Argentina

Pathological Anatomy Specialist

Mariana Beatríz del Valle Papa, Cordoba Hospital, Cordoba, Cordoba, Argentina

Head of the Blistering Diseases Office

Susana Pereyra, Cordoba Hospital, Cordoba, Cordoba, Argentina

Head of the Dermatology Service

References

I. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, et ál. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol2002;138:370-379.

II. Broussard KC, Leung TG, Ahmadreza M, Thorne JE, et ál. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol 2016;34:205-213.

III. Kim M, Borradori L, Murrell DF. Autoimmune blistering diseases in the elderly: clinical presentations and management. Drugs Aging 2016;33:711-723.

IV. Labowsky MT, Stinnett SS, Liss J, Daluvoy M, et ál. Clinical implications of direct immunofluorescence (DIF) findings in patients with ocular mucous membrane pemphigoid. Am J Ophthalmol 2017;183:48-55.

V. Queisi MM, Zein M, Lamba N, Meese H, et ál. Update on ocular cicatricial pemphigoid and emerging treatments. Surv Ophthalmol 2016;61:314-317.

VI. Espino-Barros Palau A, González-González LA, Rodríguez-García A. Presentación clínica y manejo del penfigoide cicatrizal ocular en México. Rev Mex Oftalmol 2010;84:10-18.

VII. Juri MC, Fernández Romero DS, Devoto MH, Georgiett D, et ál. Tratamiento sistémico del penfigoide cicatrizal ocular. Medicina 2012;72:103-108.

VIII. Hecht E, Pitz S, Renieri G. In-vivo confocal microscopy for the diagnosis of mucous membrane pemphigoid. Klin Monbl Augenheilkd 2015;232:1077-1081.

IX. Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010;23:268-280.

X. Oyama N, Togashi A, Nomura E, Kaneko F. Successful treatment with oral mizoribine in refractory ocular manifestation of mucosal pemphigus vulgaris: A unique response to different immunosuppressive drugs. Dermatol Ther 2016;29:442-445.

XI. You C, Lamba N, Lasave AF, Ma L, et ál. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol 2017;255:1221-1228

Published

2018-09-01

Issue

Section

Original Articles